Listed by the USPTO as BAEK, BONG-SOOK
Tech Center 1600 • Art Units: 1611 1612 1614 1615 1616 1619 1621 1624 1627 1629
This examiner grants 42% of resolved cases
BAEK, BONG-SOOK is assigned to technology center 1600 and art unit 1611. The profile covers 932 resolved cases, with a 41.7% allowance rate and a median of 1143 days to allowance. The 69.9% interview lift is substantial and indicates that interviews are a particularly important feature of this prosecution record.
The listed companies are Scai Therapeutics, Genentech, and Beam Therapeutics. The listed firms are SUGHRUE MION, Acuity Law Group, and AKERMAN. Counsel should plan for a challenging allowance environment while giving serious attention to examiner interviews. The combination of the allowance result and interview association supports preparing detailed, technically focused discussions before adopting amendments that could constrain future claim scope.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18801886 | Cardiosafe Antidiabetic Therapy | Final Rejection | Boehringer Ingelheim International GmbH |
| 18012099 | AMELIORATING AGENT OR PROPHYLACTIC AGENT FOR MUSCLE WEAKNESS SYMPTOM IN DISEASE OR SYNDROME ASSOCIATED WITH METABOLIC DISORDER | Non-Final OA | Toray Industries, Inc. |
| 18741056 | MULTICOMPONENT DEGRADABLE CATIONIC POLYMERS | Non-Final OA | The Johns Hopkins University |
| 16935005 | USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY | Final Rejection | Jazz Pharmaceuticals Research UK Limited |
| 19088104 | COMPOSITION FOR REDUCING AMOUNT OF REACTIVE OXYGEN | Non-Final OA | KANEKA CORPORATION |
| 18276929 | CORONAL PROTEIN-COATED NANOPARTICLES AND USES THEREOF | Final Rejection | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. |
| 19105710 | CARBONATED JELLY DRINK | Non-Final OA | OTSUKA PHARMACEUTICAL FACTORY, INC. |
| 18907757 | COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER | Non-Final OA | OTSUKA PHARMACEUTICAL CO., LTD. |
| 18696604 | HAIR CARE COMPOSITIONS, METHOD FOR PROVIDING IMPROVED CURLS DEFINITION TO THE HAIR AND METHOD OF TREATING HAIR | Final Rejection | L'OREAL |
| 18777264 | COMPOSITIONS AND METHODS FOR RESHAPING KERATIN-RICH SUBSTRATES AND FORMING ADHERENT FLEXIBLE FILMS | Non-Final OA | Gelest, Inc. |
| 19040204 | METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | Final Rejection | Alto Neuroscience, Inc. |
| 18700760 | ANTIMICROBIAL COMPOSITION AND METHOD FOR MAKING THE SAME | Final Rejection | WACKER CHEMIE AG |
| 18024679 | COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING BRAIN DAMAGE AND MILD COGNITIVE IMPAIRMENT COMPRISING GLUTAMINE AS EFFECTIVE COMPONENT | Non-Final OA | INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY |
| 18746791 | NANOMATERIALS COMPRISING TETRAVALENT LIPID COMPOUNDS | Non-Final OA | Beam Therapeutics Inc. |
| 18005137 | USE OF ALVERINE OR ITS DERIVATIVES FOR THE TREATMENT OF MITOCHONDRIAL DISEASES OR DYSFUNCTION ASSOCIATED WITH MITOCHONDRIAL COMPLEX I DEFICIENCIES | Non-Final OA | UNIVERSITE DE BORDEAUX |
| 18639661 | COMPOSITIONS FOR AND METHODS OF INHIBITING SARS-COV-2 INFECTION | Non-Final OA | Texas Southern University |
| 17753654 | METHOD FOR PREVENTING PRECIPITATION OF INJECTABLE SOLUTION CONTAINING p-BORONOPHENYLALANINE | Final Rejection | Stella Pharma Corporation |
| 18289726 | NASAL SLEEP FORMULATION | Final Rejection | CS MEDICA A/S |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy41.7% of resolved applications examined by Bong-Sook Baek were allowed (932 resolved cases), compared with 35.4% across Art Unit 1611 over the last five years.
This examiner's interview lift is +69.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Bong-Sook Baek took 1,143 days on average from filing to allowance.
Bong-Sook Baek examines applications in Art Unit 1611 in Tech Center 1600 (Biotechnology & Pharmaceuticals).